Albert Bourla, group president of vaccines, oncology and consumer healthcare businesses at Pfizer, discusses his company's research and development strategies, how Pfizer is responding to consumer-directed healthcare and the controversy over high drug prices. He spoke with Modern Healthcare reporter Steven Ross Johnson. See an edited version of their discussion here.
Pharma 'could have done a better job' explaining drug costs, Pfizer exec says
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.